Last reviewed · How we verify
NCT06763367
Clinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis
NA trial testing Face mask containing Centella sinensis in Rosacea in 30 participants. Not yet recruiting.
30 November 2026
Quick facts
| Lead sponsor | Nanjing First Hospital, Nanjing Medical University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 8 January 2025 |
| Primary completion | 30 November 2026 |
| Estimated completion | 30 November 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Face mask containing Centella sinensis
Conditions studied
- Rosacea — all drugs for Rosacea →
- Acne — all drugs for Acne →
- Centella — all drugs for Centella →
- Melasma — all drugs for Melasma →
Sponsor
Nanjing First Hospital, Nanjing Medical University
Who can join
Adults 18 to 60, any sex, with Rosacea or Acne. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study was to investigate the efficacy and safety of repairing facial mask containing Asiaticum asiatica in treating disjunctive skin diseases. A multi-center randomized double-blind self-half face control method was used. A computer-generated randomization method was used. Each cheek was randomly assigned to receive the snow glycoside mask and the control group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06763367
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rosacea
Currently open trials in the same condition.
- NCT07296497 — Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety · NA · recruiting
- NCT06312813 — Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With · Phase 2 · recruiting
- NCT06072066 — Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammatio · NA · recruiting
- NCT05942248 — The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis · NA · recruiting
- NCT05928169 — Determinants of Chronic Inflammatory Skin Disease Trajectories · recruiting
Other Nanjing First Hospital, Nanjing Medical University trials
Trials by the same sponsor.
- NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
- NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
- NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
- NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
- NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06763367 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
- Last refreshed: 8 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06763367.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing